ClinicalTrials.gg
CompletedNCT01250223Updated Jul 9, 2020

Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study)

An observational study in Lymphoma, Follicular, sponsored by Associazione Angela Serra per la ricerca sul cancro. Completed at 51 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-09.

Sponsored by Associazione Angela Serra per la ricerca sul cancro · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,093
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Lymphoma, Follicular with a site in Italy — 31 open to participants now, 57 under way, 19 of them phase 3. Lymphoma, Follicular · Italy.

Enrollment
2nd of 17
1,093 · median 200
Started
2003
with 1 other
Observational
17 of 149
6 open now
Registered
38th of 149
by date

Among the 149 studies in Lymphoma, Follicular with a site in Italy, this one is the 2nd largest by enrollment of the 17 observational ones that give a count, is one of 2 that started in 2003, is one of 17 observational ones, and was the 38th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

31 of the 149 studies in Lymphoma, Follicular with a site in Italy are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Lymphoma, Follicular with a site in Italy, or all of them as a file.
02

Study summary

The F2-study is a complement of the previous studies of the Follicular Lymphoma Prognostic Factors Project which permitted the development of the Follicular Lymphoma International Prognostic Index (FLIPI).

The F2-study is designed as a prospective collection of information potentially useful to predict the prognosis of newly diagnosed Follicular Lymphoma patients, and its purposes are to validate the FLIPI and to verify whether a prognostic collection of data would allow the development of a more accurate prognostic index.

Read the detailed description

So far, in patients with lymphoma a variety of studies aimed at the evaluation of prognosis have been conducted. In particular, different demographic, clinical and biological factors have shown a prognostic role in univariate and multivariate analysis, including age, gender, stage, tumor burden, bone marrow involvement, systemic symptoms, Performance status, serum lactate dehydrogenase (LDH) level, anemia, erythrocyte sedimentation rate (ESR) and beta-2 microglobulin.

The combination of those parameters has allowed the identification of several prognostic scores.

Attempts to define prognosis in follicular lymphomas begun in the late '70s. Then, when in 1993 the International Prognostic Index (IPI) was defined for aggressive lymphomas it was also applied to low-grade lymphomas leading to conflicting results, and the need for a prognostic index specifically designed for follicular lymphomas emerged.

A large study on prognosis in patients with follicular lymphoma was performed by the Italian Lymphoma Intergroup that leaded to the definition of the Italian Lymphoma Intergroup (ILI) score, based on 987 patients (Federico M et al. Blood 2000; 95(3):783-789). In 2004 the Follicular Lymphoma International Prognostic Project allowed the definition of a new score on 4167 pts with follicular lymphoma, the Follicular Lymphoma International Prognostic Index (FLIPI) (Solal-Céligny P et al. Blood 2004;104(5):1258-1265). This score is based on the evaluation of age (younger than 60 years vs 60 years or older), Ann Arbor stage (I-II vs III-IV), number of nodal sites (0-4 vs > 5 or more), Hemoglobin (Hb)level (greater than or equal 12g/dL vs lower than 12g/dL), serum Lactate Dehydrogenase (LDH) (normal vs elevated) and identifies three main groups of patients with different survival:low risk (0-1 factors); intermediate risk (2 factors); high risk (3-5 factors).

Notwithstanding the huge number of patients considered in these studies, all mentioned prognostic scores (IPI, ILI and FLIPI) are based on a retrospective analysis of archive data. This approach can introduce biases that can hamper final results. A first problem is the selection of patients that can be influenced by single institution policy and patient's or physician's related factors. Furthermore, some important variables, such as beta2-microglobulin or Erythrocyte Sedimentation Rate (ESR), that have frequently shown a high prognostic significance in univariate analysis, are hardly included in the final indexes because they are available only in a small number of patients thus loosing their value in multivariate analysis. Then, lacking homogeneous and prospectively defined criteria, retrospective evaluation of some study parameter as for example clinical response cannot be easily defined and all derived endpoints such as Failure Free Survival (FFS)or Progression Free Survival (PFS) may be biased.

Finally the results of a retrospective analysis aiming at the evaluation of survival are dependent on the type of administered treatment and with the recent advent of new drugs such as monoclonal antibodies and purine analogs that can be used also in the elderly patients the role of some established prognostic factor may have changed.

These are the reasons why we thought it would be useful to start a new study based on the prospective registration in a short period of time of patients with follicular lymphoma for whom it would be possible collect an exhaustive set of clinical data and biological information.

03

Conditions studied

  • Lymphoma, Follicular

Keywords

  • Lymphoma, Follicular
  • Prognosis
  • Progression-Free Survival
  • Outcome
  • International Cooperation
  • Data Collection
  • Prospective studies
  • Rare Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Previously-untreated patients with de novo diagnosis of Follicular Lymphoma according to World Health Organization (WHO) classification (grade 1,2,3a,3b)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with newly diagnosed follicular lymphoma
  • Patients with confirmed diagnosis of follicular lymphoma according to WHO classification (any grade)
  • Age over 18
  • Written

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,093 participants (actual)
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Time frame: 5-year

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: 5-year

  2. Event Free Survival (EFS)

    Time frame: 5-year

  3. Treatment Free Survival

    Time frame: 5-year

07

Study locations

51 sites
  • Northwestern University Feinberg School of Medicine - Department of Hematology/Oncology
    Chicago, Illinois 60611, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68022, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Academia Nacional de Medicina - Oncohematology Department, Instituto de Investigaciones Hematologicas
    Buenos Aires, Argentina
  • Centro de Internacion e Investigacion Clinica "Angelica Ocampo" - Hematologia
    Buenos Aires, Argentina
  • Charles University General Hospital - Ist Dept Medicine
    Praha, Czechia
  • Centre Hospitalier Universitaire - Hématologie
    Besancon, France
  • Institut Bergonié Comprehensive Cancer Center
    Bordeaux, France
  • Centre Jean Bernard, Clinique Victor Hugo
    Le Mans, France
  • Centre Hospitalier Univeristaire - Hématologie clinique
    Nantes, France
  • Hopital caremeau - Service de Medecine Interne B
    Nimes, France
  • CHRU Bretonneau - Oncologie medicale
    Tours, France
  • Presidio Spedali Civili
    Brescia, BS 25123, Italy
  • Azienda Ospedaliera S. Croce e Carle
    Cuneo, CN 12100, Italy
  • Azienda O.U. Vittorio Emanuele-Ferrarotto-S. Bambino
    Catania, CT 95124, Italy
  • Azienda Ospedaliera Pugliese-Ciaccio
    Catanzaro, CZ 88100, Italy
  • Ospedale Casa Sollievo della Sofferenza IRCCS
    San Giovanni Rotondo, FG 71013, Italy
  • Ospedale unico Versilia USL 12 - Divisione di Medicina II, DH Oncoematologico
    Lido di Camaiore, Lucca, Italy
  • Ospedale San Vincenzo - Ematologia e Immunologia
    Taormina, Messina, Italy
  • Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte
    Messina, ME 98158, Italy
  • Istituto Clinico Humanitas
    Milano, MI 20089, Italy
  • Istituto Scientifico Universitario San Raffaele
    Milano, MI 20132, Italy
  • Istituto Europeo di Oncologia
    Milano, MI 20142, Italy
  • Ospedale Madonna delle Grazie
    Matera, Mount 75100, Italy
  • Dipartimento di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio, Univ. di Modena e Reggio Emilia - Ematologia
    Modena, MO 41100, Italy
  • Dipartimento di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio, Univ. di Modena e Reggio Emilia - Medicina Interna
    Modena, MO 41100, Italy
  • Dipartimento di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio, Univ. di Modena e Reggio Emilia - Oncologia II
    Modena, MO 41100, Italy
  • Casa di Cura La Maddalena
    Palermo, Pa 90100, Italy
  • Ospedale civile Guglielmo da Saliceto - Medicina Oncologica ed Ematologica
    Piacenza, PC, Italy
  • Ospedale Santo Spirito, USL di Pescara - Dipartimento di Oncologia
    Pescara, PE, Italy
  • Policlinico Monteluce - Divisione di Clinica Medica
    Perugia, PG, Italy
  • Azienda Ospedaliera Universitaria Pisana - UO di Ematologia
    Pisa, PI, Italy
  • Fondazione IRCCS Policlinico San Matteo - Clinica Ematologica
    Pavia, PV, Italy
  • Azienda Ospedaliera S. Carlo - Oncologia Medica
    Potenza, PZ, Italy
  • Azienda Ospedaliera Bianchi-Melacrino-Morelli
    Reggio Calabria, RC 89100, Italy
  • Arcispedale S. Maria Nuova
    Reggio Emilia, RE 42100, Italy
  • Ospedale E. Morelli - Divisione di Medicina Generale, Ematologia
    Sondalo, Sondrio, Italy
  • Azienda Ospedaliera Universitaria San Giovanni Battista
    Torino, TO 10126, Italy
  • Policlinico Universitario a gestione diretta - Divisione di Ematologia
    Udine, UD, Italy
  • Ospedale Civile SS. Giovanni e Paolo - UO di Ematologia
    Venezia, VE, Italy
  • Azienda Ospedaliera Maggiore della Carità
    Novara, 28100, Italy
  • Azienda Ospedaliera Sant'Andrea - UOC Ematologia
    Roma, Italy
  • Ospedale Sant'Eugenio - Ematologia
    Roma, Italy
  • Università la Sapienza, Dip. di Biotecnologie Cellulari ed Ematologia, Sez. Ematologia
    Roma, Italy
  • Hospital Universitari Germans Trias i Pujol - Institut Català d'Oncologia
    Badalona, Spain
  • Hospital Clinic - Institut d'Hematologia i Oncologia
    Barcelona, Spain
  • Hospital Universitario Vall de Hebron - Servei d'Hematologia Clinica
    Barcelona, Spain
  • Institu Catala d'Oncologia - Servei d'Hematologia
    Girona, Spain
  • Hospital Clinico Universitario
    Valencia, Spain
  • Ospedale S. Giovanni
    Bellinzona, TI 6500, Switzerland
  • Barths and The London NHS Trust
    London, EC1A 7BE, United Kingdom
08

References and documents

Publications

  • Federico M, Bellei M, Pro B, Lopez-Guillermo A, Marcheselli L, Trneny M, Soubeyran P, MCLaughlin P, Pileri S, Solal-Céligny P on behalf of the F2 study. Revalidation of FLIPI in patients with Follicular Lymphoma (FL) registered in the F2 study and treated upfront with immunochemotherapy. J Clin Oncol 25(18s), 2007. Abstr 8008.
  • Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Martelli M, Soubeyran P, Cortelazzo S, Martinelli G, Pileri S, McLaughlin P, Solal-Céligny P on behalf of International Follicular Lymphoma Prognostic factor Project (IFLPFP) F2-study group. F2 prognostic index. Ann Oncol 19(suppl 4):101-102, 2008. Abstr 058.
  • Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Celigny P. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009 Sep 20;27(27):4555-62. doi: 10.1200/JCO.2008.21.3991. Epub 2009 Aug 3. PubMed 19652063 ↗
  • Solal-Celigny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, Luminari S, Pro B, Montoto S, Ferreri AJ, Deconinck E, Milpied N, Gordon LI, Federico M. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012 Nov 1;30(31):3848-53. doi: 10.1200/JCO.2010.33.4474. Epub 2012 Sep 24. PubMed 23008294 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of May 2008 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2010
First posted
Nov 30, 2010
Start
Feb 2003
Primary completionActual
May 2008
CompletionActual
Dec 2016
Last update
Jul 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01250223
Lead sponsor
Associazione Angela Serra per la ricerca sul cancro
Collaborators
Fondazione Italiana Linfomi - ETS, The International Non-Hodgkin Lymphoma Prognostic Factor Project
Responsible party
Sponsor
First posted
Nov 30, 2010
Start date
Feb 2003
Primary completion
May 2008
Completion
Dec 2016
Last update
Jul 9, 2020

Study contacts

Massimo Federico, MD
study chair · Dip. Oncologia, Ematologia e Patologie dell'Apparato Respiratorio - Università di Modena e Reggio Emilia, Modena, Italy
Philippe Solal-Céligny, MD
study chair · Centre Jean Bernard, Le Mans, France
Armando Lopez-Guillermo, MD
study chair · Institut d'Hematologia i Oncologia, Hospital Clinic, Barcelona, Spain
Peter McLaughlin, MD
study chair · UT MD Anderson Cancer Ctr, Houston, TX, USA
Umberto Vitolo, MD
study chair · Azienda Universitaria Ospedaliera San Giovanni Battista, Torino, Italy
Stefano A. Pileri, MD
study chair · Instituto Seragnoli, Unità Operativa di Emolinfopatologia, Università di Bologna, Bologna, Italy

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion